Mack Mabry

3.9k total citations · 1 hit paper
31 papers, 1.8k citations indexed

About

Mack Mabry is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Mack Mabry has authored 31 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 15 papers in Oncology and 11 papers in Hematology. Recurrent topics in Mack Mabry's work include Acute Myeloid Leukemia Research (11 papers), Lung Cancer Research Studies (5 papers) and Cancer therapeutics and mechanisms (5 papers). Mack Mabry is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Lung Cancer Research Studies (5 papers) and Cancer therapeutics and mechanisms (5 papers). Mack Mabry collaborates with scholars based in United States, Australia and Germany. Mack Mabry's co-authors include Barry D. Nelkin, Stephen B. Baylin, Michael Borges, Douglas W. Ball, Herbert Chen, Helgi J. K. van de Velde, R. Ilona Linnoila, Martin Dunbar, Jalaja Potluri and Brenda Chyla and has published in prestigious journals such as Nature, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Mack Mabry

30 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

2018 498 citations Courtney D. DiNardo, Keith W. Pratz et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mack Mabry United States	19	1.2k	611	534	205	196	31	1.8k
Simone Boehrer Germany	24	1.0k 0.8×	620 1.0×	367 0.7×	415 2.0×	108 0.6×	68	1.7k
Björn Hackanson Germany	21	1.2k 1.0×	583 1.0×	341 0.6×	180 0.9×	65 0.3×	51	1.7k
Aaron J. Donner United States	15	1.1k 0.9×	655 1.1×	354 0.7×	250 1.2×	112 0.6×	18	2.1k
Akihide Yoshimi Japan	23	994 0.8×	683 1.1×	231 0.4×	250 1.2×	97 0.5×	64	1.6k
Goro Sashida Japan	28	2.0k 1.6×	1.1k 1.8×	390 0.7×	404 2.0×	115 0.6×	88	2.7k
Francesco Paolo Tambaro United States	16	789 0.7×	294 0.5×	309 0.6×	262 1.3×	106 0.5×	40	1.3k
Marina R. Carpinelli Australia	15	855 0.7×	484 0.8×	249 0.5×	265 1.3×	104 0.5×	30	1.5k
Dana E. Cullen United States	11	1.5k 1.2×	751 1.2×	329 0.6×	465 2.3×	64 0.3×	15	2.2k
Antonella Gozzini Italy	22	752 0.6×	1.0k 1.7×	408 0.8×	533 2.6×	62 0.3×	75	1.7k
Christina Halsey United Kingdom	19	599 0.5×	352 0.6×	238 0.4×	239 1.2×	81 0.4×	36	1.3k

Countries citing papers authored by Mack Mabry

Since Specialization

Citations

This map shows the geographic impact of Mack Mabry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mack Mabry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mack Mabry more than expected).

Fields of papers citing papers by Mack Mabry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mack Mabry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mack Mabry. The network helps show where Mack Mabry may publish in the future.

Co-authorship network of co-authors of Mack Mabry

This figure shows the co-authorship network connecting the top 25 collaborators of Mack Mabry. A scholar is included among the top collaborators of Mack Mabry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mack Mabry. Mack Mabry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DiNardo, Courtney D., Keith W. Pratz, Anthony Letai, et al.. (2018). Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet Oncology. 19(2). 216–228. 498 indexed citations breakdown →

Pollyea, Daniel A., Courtney D. DiNardo, Michael J. Thirman, et al.. (2016). Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy.. Journal of Clinical Oncology. 34(15_suppl). 7009–7009. 38 indexed citations

Chyla, Brenda, Relja Popovic, Jalaja Potluri, et al.. (2016). Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia. Blood. 128(22). 1709–1709. 7 indexed citations

Hogdal, Leah J., Brenda Chyla, Evelyn McKeegan, et al.. (2015). Abstract B10: Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia.. Clinical Cancer Research. 21(17_Supplement). B10–B10. 1 indexed citations

Cleary, James M., Caio Max S. Rocha Lima, Herbert I. Hurwitz, et al.. (2014). A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Investigational New Drugs. 32(5). 937–945. 59 indexed citations

Konopleva, Marina, Daniel A. Pollyea, Jalaja Potluri, et al.. (2014). A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML). Blood. 124(21). 118–118. 50 indexed citations

Vlahovic, Gordana, Vassiliki Karantza, Ding Wang, et al.. (2014). A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. Investigational New Drugs. 32(5). 976–984. 46 indexed citations

Ravi, Rajani, Arunthathi Thiagalingam, Erich Weber, et al.. (1999). Raf-1 Causes Growth Suppression and Alteration of Neuroendocrine Markers in DMS53 Human Small-Cell Lung Cancer Cells. American Journal of Respiratory Cell and Molecular Biology. 20(4). 543–549. 42 indexed citations

Ravi, Rajani, Martin McMahon, Jerry R. Williams, et al.. (1999). Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. Journal of Cellular Biochemistry. 72(4). 458–469. 64 indexed citations

10.

Weber, Erich, Rajani Ravi, Erik S. Knudsen, et al.. (1999). Retinoic acid-mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 Expression. International Journal of Cancer. 80(6). 935–943. 34 indexed citations

11.

Kalemkerian, Gregory P., et al.. (1998). A Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma. Cancer. 83(6). 1102–1108. 27 indexed citations

12.

Borges, Michael, R. Ilona Linnoila, Helgi J. K. van de Velde, et al.. (1997). An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 386(6627). 852–855. 339 indexed citations

13.

Thiagalingam, Arunthathi, A de Bustros, Michael Borges, et al.. (1996). RREB-1, a Novel Zinc Finger Protein, Is Involved in the Differentiation Response to Ras in Human Medullary Thyroid Carcinomas. Molecular and Cellular Biology. 16(10). 5335–5345. 123 indexed citations

14.

Mabry, Mack, et al.. (1996). Mechanism of all-trans-retinoic acid-mediated L-myc gene regulation in small cell lung cancer.. PubMed. 13(9). 1893–9. 9 indexed citations

15.

Williams, Jerry R., James Russell, J. F. Dicello, & Mack Mabry. (1996). The genotype of the human cancer cell: Implications for risk analysis. Mutation Research/Reviews in Genetic Toxicology. 365(1-3). 17–42. 8 indexed citations

16.

Akhtar, Adil, Gauri C. Bedi, David Sidransky, et al.. (1996). Selective radiosensitization of p53–deficient cells by caffeine–mediated activation of p34cdc2 kinase. Nature Medicine. 2(10). 1140–1143. 139 indexed citations

17.

Wu, Jian, James G. Herman, Geoffrey G. Wilson, et al.. (1996). Expression of prokaryotic HhaI DNA methyltransferase is transforming and lethal to NIH 3T3 cells.. PubMed. 56(3). 616–22. 24 indexed citations

18.

Kaufmann, Scott H., et al.. (1995). Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide, and camptothecin. Biochemical Pharmacology. 50(12). 1987–1993. 7 indexed citations

19.

Nelkin, Barry D., et al.. (1990). Transcription factor levels in medullary thyroid carcinoma cells differentiated by Harvey ras oncogene: C-jun in increased. Biochemical and Biophysical Research Communications. 170(1). 140–146. 8 indexed citations

20.

Bernal, Samuel D., et al.. (1985). Selective cytotoxicity of the SM1 monoclonal antibody towards small cell carcinoma of the lung.. PubMed. 45(3). 1026–32. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact